Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
2.
Cancer Cell ; 38(5): 602-604, 2020 11 09.
Article in English | MEDLINE | ID: covidwho-970849

ABSTRACT

To understand the real impact of COVID-19 on cancer patients, an entirely new data collection effort was initiated within the Thoracic Cancers International COVID-19 Collaboration (TERAVOLT). TERAVOLT reported high mortality related to COVID-19 infection in thoracic cancer patients and identified several negative prognostic factors. In this commentary, we discuss the importance and limits of patient registries to support decision-making in thoracic cancer during the SARS-CoV-2 pandemic.


Subject(s)
Betacoronavirus/isolation & purification , Clinical Decision-Making , Coronavirus Infections/complications , Global Burden of Disease/standards , Pneumonia, Viral/complications , Practice Guidelines as Topic/standards , Thoracic Neoplasms/therapy , COVID-19 , Coronavirus Infections/virology , Humans , International Cooperation , Pandemics , Pneumonia, Viral/virology , Registries , SARS-CoV-2 , Thoracic Neoplasms/epidemiology , Thoracic Neoplasms/virology
4.
Cancer Discov ; 10(8): 1121-1128, 2020 08.
Article in English | MEDLINE | ID: covidwho-245491

ABSTRACT

The coronavirus disease 2019 (COVID-19) pandemic has led to dramatic changes in oncology practice. It is currently unknown whether programmed death 1 (PD-1) blockade therapy affects severity of illness from COVID-19 in patients with cancer. To address this uncertainty, we examined consecutive patients with lung cancers who were diagnosed with COVID-19 and examined severity on the basis of no or prior receipt of PD-1 blockade. Overall, the severity of COVID-19 in patients with lung cancer was high, including need for hospitalization in more than half of patients and death in nearly a quarter. Prior PD-1 blockade was, as expected, associated with smoking status. After adjustment for smoking status, PD-1 blockade exposure was not associated with increased risk of severity of COVID-19. PD-1 blockade does not appear to affect the severity of COVID-19 in patients with lung cancers. SIGNIFICANCE: A key question in oncology practice amidst the COVID-19 pandemic is whether PD-1 blockade therapy affects COVID-19 severity. Our analysis of patients with lung cancers supports the safety of PD-1 blockade treatment to achieve optimal cancer outcomes.This article is highlighted in the In This Issue feature, p. 1079.


Subject(s)
Coronavirus Infections , Coronavirus , Lung Neoplasms , Pandemics , Pneumonia, Viral , Betacoronavirus , COVID-19 , Humans , Programmed Cell Death 1 Receptor , SARS-CoV-2
SELECTION OF CITATIONS
SEARCH DETAIL
...